New shot could stop deadly clots in cancer patients
NCT ID NCT07410117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks for side effects like bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN7508 (cenvacibart), a monoclonal antibody
What this could lead to
If successful, this could provide a new way to prevent dangerous blood clots in people with cancer, reducing the risk of stroke or death.
What could go wrong
This is still experimental. The drug may not work better than placebo, and there is a risk of bleeding or other side effects. Results are not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER-ASSOCIATED THROMBOSIS (CAT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Hospital Tbilisi
RECRUITINGTbilisi, 0102, Georgia
-
Bioresearch Partner- Hialeah Hospital
RECRUITINGHialeah, Florida, 33013, United States
-
Caucasus Medical Centre
RECRUITINGTbilisi, 0186, Georgia
-
El Paso Medical Research Institute (Medresearch Inc)
RECRUITINGEl Paso, Texas, 79902, United States
-
Helios Clinical Research
RECRUITINGNorth Miami Beach, Florida, 33169, United States
-
Institute of Clinical Oncology
RECRUITINGTbilisi, 0159, Georgia
-
JSC Evex Hospitals - Caraps Medline
RECRUITINGTbilisi, 0179, Georgia
-
Krystyna Kiel Oncology Center
RECRUITINGKutaisi, Imereti, 4600, Georgia
-
LTD Cancer Research Centre
RECRUITINGTbilisi, 0179, Georgia
-
LTD High Technology Hospital Medcenter
RECRUITINGBatumi, Adjara, 6000, Georgia
-
Llc Todua Clinic
RECRUITINGTbilisi, 0112, Georgia
-
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
RECRUITINGTbilisi, 0144, Georgia